Cannabis may help in the treatment of Parkinson’s Disease, according to a new study published in the journal Neurotherapeutics and published online by the U.S. National Institute of Health.
“Previous studies suggest that the endocannabinoid system plays an important role in the neuropathological basis of Parkinson’s disease (PD)”, begin’s the study’s abstract. “This study was designed to detect potential alterations in the cannabinoid receptors CB1 (CB1r) and CB2 (A isoform, CB2Ar), and in monoacylglycerol lipase (MAGL) gene expression in the substantia nigra (SN) and putamen (PUT) of patients with PD.”
According to researchers, the results of the present study “suggest that CB1r, CB2r, and MAGL are closely related to the neuropathological processes of PD.” Therefore, “the pharmacological modulation of these targets [such as through the consumption of cannabis] could represent a new potential therapeutic tool for the management of PD.”
For the full text of the study – conducted by researchers at Miguel Hernández University-CSIC, Instituto de Salud Carlos III and Universidad de Navarra – click here.